SLC19A1 Antikörper (N-Term)

Produktnummer ABIN310565

Es sind 2+ Publikationen für dieses Produkt verfügbar. Der Kaninchen Polyklonal anti-SLC19A1 Antikörper wird verwendet zum Nachweis von SLC19A1 in Proben von Human. Er wurde validiert für WB und IHC.

Kurzübersicht für SLC19A1 Antikörper (N-Term) (ABIN310565)

Target: SLC19A1 (Solute Carrier Family 19 (Folate Transporter), Member 1 (SLC19A1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SLC19A1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Produktdetails anti-SLC19A1 Antikörper

Bindungsspezifität: N-Term

Sequenz: MVPSSPAVEK QVPVEPGPDP ELRSWRHLVC YLCFYGFMAQ IRPGESFITP

Homologie: Human: 100%

Produktmerkmale: This is a rabbit polyclonal antibody against SLC19A1. It was validated on Western Blot and immunohistochemistry.

Aufreinigung: Protein A purified

Immunogen: The immunogen is a synthetic peptide directed towards the N terminal region of human SLC19A1

Anwendungsinformationen

Applikationshinweise: Optimal working dilutions should be determined experimentally by the investigator.

Kommentare:

Antigen size: 591 AA

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Referenzen für anti-SLC19A1 Antikörper (ABIN310565)

Halwachs, Lakoma, Schäfer, Seibel, Honscha: "The antiepileptic drugs phenobarbital and carbamazepine reduce transport of methotrexate in rat choroid plexus by down-regulation of the reduced folate carrier." in: Molecular pharmacology, Vol. 80, Issue 4, pp. 621-9, (2011) (PubMed).

Marchi, Paoluzzi, Scotto, Seshan, Zain, Zinzani, OConnor: "Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 16, Issue 14, pp. 3648-58, (2010) (PubMed).

Details zu SLC19A1

Target: SLC19A1 (Solute Carrier Family 19 (Folate Transporter), Member 1 (SLC19A1))

Andere Bezeichnung: SLC19A1

Hintergrund: Transport of folate compounds into mammalian cells can occur via receptor-mediated or carrier-mediated mechanisms. A functional coordination between these 2 mechanisms has been proposed to be the method of folate uptake in certain cell types. Methotrexate (MTX) is an antifolate chemotherapeutic agent that is actively transported by the carrier-mediated uptake system. SLC19A1 plays a role in maintaining intracellular concentrations of folate.Transport of folate compounds into mammalian cells can occur via receptor-mediated (see MIM 136430) or carrier-mediated mechanisms. A functional coordination between these 2 mechanisms has been proposed to be the method of folate uptake in certain cell types. Methotrexate (MTX) is an antifolate chemotherapeutic agent that is actively transported by the carrier-mediated uptake system. RFC1 plays a role in maintaining intracellular concentrations of folate.[supplied by OMIM].
Alias Symbols: CHMD, FOLT, IFC1, REFC, RFC1
Protein Interaction Partner: UBC,
Protein Size: 591

Molekulargewicht: 65 kDa

Gen-ID: 6573

NCBI Accession: NM_194255, NP_919231

UniProt: P41440

Pathways: Dicarboxylic Acid Transport